

**PHARMANUTRA S.P.A. CONSOLIDATES ITS POSITION IN EUROPE:
PARTNERSHIP SIGNED FOR THE DISTRIBUTION OF SIDERAL® PRODUCTS
IN FRANCE AND SWITZERLAND**

THE GROUP SIGNS AN AGREEMENT WITH THE FRENCH MULTINATIONAL PILEJE

Pisa, March 3rd 2026 – [Pharmanutra S.p.A.](#) (MTA; Ticker PHN), a company specialized in mineral-based nutritional supplements and medical devices for muscles and joints, announces that it has signed a new distribution agreement for France and Switzerland. The contract has been finalized with the French multinational PiLeJe, a leading company in the nutraceutical market operating in several European countries through its own subsidiaries. For over 30 years, it has been designing and developing— in close collaboration with public research institutes and organizations—specific ingredients and finished products based on probiotics and micronutrients.

Founded in 1991, PiLeJe is a French family-owned group specializing in the development, manufacturing, and marketing of food supplements and health solutions based on micronutrition and phytotherapy. The company primarily operates through healthcare professionals' channels, particularly physicians and pharmacists, both in France and internationally. Certified B Corp in 2025 and aligned with a climate pathway validated by the Science Based Targets initiative (SBTi), PiLeJe advances through a responsible and sustainable growth model.

Under this agreement with Pharmanutra, PiLeJe will distribute two Sucrosomial® Iron-based food supplements on the French market, SiderAL® Oro sticks and SiderAL® Forte capsules, under the brand name FORFERAL®.

Developed using Sucrosomial® Technology, the proprietary delivery system patented by the Pisa-based Group and capable of protecting micronutrient molecules such as iron - thereby increasing absorption and improving gastrointestinal tolerability - FORFERAL® Fer and FORFERAL® Fer-B Complex will be distributed in France starting next September, after an intensive scientific and commercial training program and dedicated events for the sales force and health care professionals.

PiLeJe will also handle the distribution of some Pharmanutra's products in Switzerland, under the brands Pileje eisen Forte and Pileje eisen Active. These iron supplements are based on the Sucrosomial®, technology as well, the groundbreaking system that, in March of last year, was included— as the only

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



recognized oral iron— in the World Health Organization guidelines for the treatment of anaemia as a valid alternative to intravenous iron, particularly in the context of cardiovascular diseases and diabetes.

The partnership between Pharmanutra and PiLeJe - two excellences in the nutraceutical field of their respective countries which share a strong innovative vision - represents a high-value strategic achievement and paves the way for an even more ambitious and structured collaboration in the upcoming years.

Andrea Lacorte (President of Pharmanutra S.p.A.) comments:

"We are very pleased to have signed an agreement with one of the most important companies in the nutraceutical sector, perfectly aligned with our vision ideal for realizing our ambitions and promoting our products on the French market. France is one of our strategic target countries, and this agreement with such a prestigious partner represents another significant step forward in our continuous international expansion. We are truly excited to develop our business with such a first-class and innovative company, convinced that this is only the first step in a common path that will generate great value".

Pascaline Gervoson (President of PiLeJe) adds:

"I am pleased to initiate this partnership with Pharmanutra. This collaboration reflects our commitment to providing healthcare professionals with high-standard solutions grounded in scientific quality, traceability, and industrial expertise. We share a common vision: that of sustainable, responsible, and rigorous healthcare".

Pharmanutra S.p.A.

Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence. Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine).

PharmanutraGroup.com

Pharmanutra.it

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



For further information:

Pharmanutra S.p.A.

Via Campodavella 1 - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it

Ufficio Stampa Interno

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milano

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Pharmanutra S.p.A.

Via Campodavella, 1 - 56122 Pisa | +39 050 7846500

pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it

C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259

